Autologous Tumor Infiltrating Lymphocytes LN-145 clinical trials
Also written LN-145.
Its developmentBy Iovance Biotherapeutics and Shanghai Juncell Therapeutics, step by step8 company-led studies, furthest phase 2: when each phase was reached, its deals, target and what is ahead.How each study uses Autologous Tumor Infiltrating Lymphocytes LN-145 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Autologous Tumor Infiltrating Lymphocytes LN-145 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2017 (2); 1 more planned to start later
| Year | Studies |
|---|---|
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 1 |
| 2023 | 1 |
| 2024 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 7
Iovance Biotherapeutics, Inc. (6) · Vastra Gotaland Region (2) · Shanghai Juncell Therapeutics (2) · M.D. Anderson Cancer Center (1) · Karam Khaddour, MD, MS (1) · Zhiyong Huang (1) · Gregory Daniels (1) · Roswell Park Cancer Institute (1)
Often tested with
Tested in the same studies.
Lifileucel (12) · Autologous Tumor Infiltrating Lymphocytes LN-145-S1 (2) · Melphalan (1) · Interleukin-2 (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test Autologous Tumor Infiltrating Lymphocytes LN-145.
- Jan 2027A Phase Ib Study of GC101 in NSCLCPhase 1 · Shanghai Juncell Therapeutics
- Apr 2027LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue SarcomasPhase 2 · M.D. Anderson Cancer Center
- Jun 2027A Phase II Study of GC101 in NSCLCPhase 2 · Shanghai Juncell Therapeutics
Studies
Open first, then newest update. How each study uses Autologous Tumor Infiltrating Lymphocytes LN-145 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 15
- Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver MetastasesNot yet recruitingPhase 1Vastra Gotaland RegionNCT05903937Written as Autologous Tumor Infiltrating Lymphocytes
- A Phase Ib Study of GC101 in NSCLCRecruitingPhase 1Shanghai Juncell TherapeuticsNCT06473961Written as Autologous Tumor Infiltrating Lymphocytes
- A Phase II Study of GC101 in NSCLCRecruitingPhase 2Shanghai Juncell TherapeuticsNCT07560111Written as Autologous Tumor Infiltrating Lymphocytes
- Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung CancerRecruitingPhase 2Iovance Biotherapeutics, Inc.NCT04614103Written as LN-145
- TIL Therapy in cSCC and MCCRecruitingPhase 2Karam Khaddour, MD, MSNCT07288073Written as LN-145
- Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Advanced Liver CancerRecruitingPhase 1Zhiyong HuangNCT06084299Written as Autologous Tumor Infiltrating Lymphocytes
- LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue SarcomasActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT03449108Written as Autologous Tumor Infiltrating Lymphocytes LN-145
- Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult ParticipantsTerminatedPhase 1Iovance Biotherapeutics, Inc.NCT06566092Written as LN-145/LN-144
- Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical CarcinomaTerminatedPhase 2Iovance Biotherapeutics, Inc.NCT03108495Written as LN-145
- Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid TumorsTerminatedPhase 2Iovance Biotherapeutics, Inc.NCT03645928Written as LN-145
- Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver MetastasesCompletedPhase 1Vastra Gotaland RegionNCT04812470Written as Autologous Tumor Infiltrating Lymphocytes
- Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid TumorsTerminatedPhase 1Gregory DanielsNCT03991741Written as Autologous Tumor Infiltrating Lymphocytes
- Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & NeckCompletedPhase 2Iovance Biotherapeutics, Inc.NCT03083873Written as LN-145
- Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based ChemotherapyWithdrawnPhase 2Roswell Park Cancer InstituteNCT03935347Written as Autologous Tumor Infiltrating Lymphocytes LN-145
- Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung CancerWithdrawnPhase 2Iovance Biotherapeutics, Inc.NCT03419559Written as LN-145